Apogee Therapeutics, Inc.
APGE
$38.40
$2.055.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 59.97% | 76.53% | 90.85% | 79.27% | 121.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.82% | 65.25% | 104.23% | 141.46% | 133.64% |
| Operating Income | -65.82% | -65.25% | -104.23% | -141.46% | -133.64% |
| Income Before Tax | -95.24% | -72.17% | -111.75% | -135.21% | -79.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.46% | -72.43% | -111.81% | -135.21% | -79.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.46% | -72.43% | -111.81% | -135.21% | -79.06% |
| EBIT | -65.82% | -65.25% | -104.23% | -141.46% | -133.64% |
| EBITDA | -65.05% | -64.84% | -- | -- | -- |
| EPS Basic | -89.04% | -48.69% | -79.03% | -70.78% | 84.16% |
| Normalized Basic EPS | -88.82% | -48.46% | -78.97% | -70.75% | 84.16% |
| EPS Diluted | -89.04% | -48.69% | -79.03% | -70.78% | 84.16% |
| Normalized Diluted EPS | -88.82% | -48.46% | -78.97% | -70.75% | 84.16% |
| Average Basic Shares Outstanding | 3.39% | 15.95% | 18.30% | 37.75% | 1,030.30% |
| Average Diluted Shares Outstanding | 3.39% | 15.95% | 18.30% | 37.75% | 1,030.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |